Elicio Therapeutics, a Cambridge, MA-based immuno-oncology company, closed its $33m Series B financing.
Backers included Clal Biotechnology Industries, Livzon Pharmaceutical Group and Efung Capital.
The company intends to use the funds to advance its pipeline of novel lymph node targeted immuno-therapies, including ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS). ELI-002 targets all seven KRAS mutations that drive 99% of all mKRAS-driven cancers, estimated to be 25% of all human solid tumors.
Led by Robert Connelly, CEO, Elicio Therapeutics combines expertise in materials science and immunology to engineer potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers. Its lead Amphiphile vaccine targeting KRAS-driven cancers will begin initial patient studies in pancreatic and colorectal cancer patients in the first half of 2020.
These programs are followed by a broad preclinical pipeline of lymph node targeted immunotherapies.
The AMP KRAS vaccine ELI-002 has completed preclinical validation, IND-enabling GLP toxicology studies, GMP manufacturing, and a pre-IND meeting with the FDA and the company intends to begin an initial patient study in pancreatic cancer patients in the first half of 2020. These trials will be multi-site, randomized, controlled studies. Initial ELI-002 pancreatic cancer patient data is expected in the second half of 2020.